Navigation Links
Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
Date:5/12/2008

ANN ARBOR, Mich., May 12 /PRNewswire/ -- Velcura Therapeutics, Inc. announced the successful completion of a first-in-man clinical trial for its lead compound, VEL-0230, which the company is investigating as a treatment for Rheumatoid Arthritis (RA) and other bone diseases. In extensive preclinical studies, VEL-0230 proved to be a powerful anti-inflammatory agent that also stimulates bone formation and inhibits bone loss. Taken together, these characteristics strongly suggest this drug may be an important therapy for RA patients.

"The successful completion of the first studies in healthy human volunteers is an important milestone in developing VEL-0230 as a therapy," said Michael W. Long, PhD, President and Chief Executive Officer of Velcura. "While we are still analyzing and tabulating the data, our preliminary conclusions are that the drug is safe and well-tolerated over a range of doses."

"During this initial safety study in humans, the drug caused a rapid (within 15 minutes) and marked (80%) reduction in CTx levels, a biomarker of bone resorption. Our next step is to evaluate the drug for efficacy in RA patients," said Dr. Long who added, "We plan to move into multiple clinical studies as rapidly as possible."

VEL-0230 is being studied as an orally available molecule that promotes bone formation, inhibits bone loss and reduces inflammation. If successful in RA patients Velcura Therapeutics plans to study it as a treatment for other bone disorders, such as bone loss related to multiple myeloma, bone metastases, and osteoporosis.

About Velcura Therapeutics, Inc.

Velcura Therapeutics, Inc. is an early stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops highly differentiated therapies for bone disease; specifically, therapies that restore the balance between bone building an
'/>"/>

SOURCE Velcura Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
2. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
9. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
10. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... HILL, N.C. , Dec. 19, 2014 /PRNewswire/ ... to optimize a product,s web presence to reflect ... Brand websites, in particular, must meet the needs ... regulations and culture. According to ... more than half of the participating companies averaged ...
(Date:12/19/2014)... 18, 2014 Somewhere between dropping five pounds ... forgotten. But Audicus , a next-generation hearing aids ... new year. Hearing loss is the third ... though it is often unaddressed. Forty-eight million Americans have ... hearing aid, mainly due to price. Hearing aids traditionally ...
(Date:12/19/2014)... Dec. 18, 2014  RESMED INC. (NYSE: RMD ... of fiscal year 2015 results on Thursday, January 22, 2015, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2Audicus Will Help People Resolve to Hear Better in 2015 2ResMed To Announce Second Quarter 2015 Results 2
... Nov. 23 Immucor, Inc. (Nasdaq: BLUD ), a ... transfusion industry, today announced that access to its presentation at ... York, NY will be available via a live, simultaneous webcast. ... December 1, 2009, at 12:30 p.m. Eastern time. Access to ...
... , POINT RICHMOND, Calif., Nov. 23 ... that it is scheduled to meet with the U.S. Food ... the Complete Response Letter regarding the New Drug Application (NDA) ... As previously announced, the Complete Response Letter, received by Transcept ...
Cached Medicine Technology:Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter 2
(Date:12/22/2014)... 2014 On December 22, 2014, My ... Gordon Cashwell for an episode to celebrate Christmas. At ... is it so important to you that we all ... “We all should respect who Jesus was. I think ... Christian beliefs. That means that on Jesus’ birthday we ...
(Date:12/22/2014)... 2014 Physicians in China are most ... treatment of non-Hodgkin’s lymphoma (NHL), according to a new ... healthcare consulting firm. MabThera is the only biologic available ... common form of NHL. , According to Kantar Health’s ... incidence of NHL in China has been growing and ...
(Date:12/22/2014)... 2014 Give a loved one the ... of health and vitality. , For a limited time, ... anti-aging formulas in special Holiday Wellness gift packages at ... , Each bottle contains cutting-edge, proven nutritional support for ... as well as we age. , Joint ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 NAPW ... 2014 Professional Woman of the Year. She is recognized ... the largest, most recognized networking organization of professional women ... the National Association of Professional Women is a vibrant ... Local Chapters. , Ms. Kreider is passionate and committed ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2
... By Amanda Gardner HealthDay Reporter , TUESDAY, April ... take calcium supplements to prevent bone deterioration may, in fact, be ... previous studies with similar findings, the new conclusions don,t necessarily mark ... study released online April 19 in the BMJ . ...
... at the University of Pennsylvania School of Medicine are delving ... of chromosomes. Recent work, e-published in Nature Structural & ... telomeres, can be protected by caps made up of specialized ... Telomere caps are like a knot at the end of ...
... major discovery about an enzyme,s structure has opened a window ... have determined the structure of a nuclease that will help ... for cancer research. DNA repair pathways are very important ... tools the cell uses to do those repairs are not ...
... that will test whether heart disease drugs can be used ... class of drugs - known as statins - can prevent ... cent of pregnant women in the UK. The ... research showing that statins, which are prescribed to lower heart ...
... HealthDay Reporter , TUESDAY, April 19 (HealthDay News) -- ... to curb misuse of extended-release and long-acting opioid pain killers ... Risk Evaluation and Mitigation Strategy (REMS) is part of a ... reduce overall prescription drug abuse in the United States. ...
... The European College of Neuropsychopharmacology (ECNP) is pleased ... the 2011 ECNP Neuropsychopharmacology Award in Basic Science ... the brain adenosine system. The ECNP Neuropsychopharmacology Award ... neuropsychopharmacology and closely related disciplines. The award is ...
Cached Medicine News:Health News:Women Taking Calcium Supplements May Risk Heart Health, Researchers Say 2Health News:Women Taking Calcium Supplements May Risk Heart Health, Researchers Say 3Health News:Ends of chromosomes protected by stacked, coiled DNA caps 2Health News:Ends of chromosomes protected by stacked, coiled DNA caps 3Health News:Nature's elegant solution to repairing DNA in cancer, other conditions 2Health News:Heart drugs could cut blood pressure risks in pregnancy 2Health News:FDA Looks to Crack Down on Misuse of Opioid Painkillers 2Health News:Bertil Fredholm wins the 2011 ECNP Neuropsychopharmacology Award in basic science research 2
For the direct colorimetric determination of alkaline phosphatase in human serum....
Auto LDL-Cholesterol, automated analyzer test kits....
For the quantitative determination of uric acid in serum....
For the quantitative determination of uric acid in serum....
Medicine Products: